Related Experiment Video
Updated: May 10, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Boron neutron capture therapy for recurrent high-grade meningiomas
Shinji Kawabata1, Ryo Hiramatsu, Toshihiko Kuroiwa
1Department of Neurosurgery, Osaka Medical College, Takatsuki;
Journal of Neurosurgery
|July 2, 2013
Summary
Boron neutron capture therapy (BNCT) shows promise for treating difficult high-grade meningiomas. This particle radiation therapy, using (18)F-BPA PET for targeting, achieved significant tumor reduction and improved patient symptoms.
Area of Science:
- Oncology
- Radiation Oncology
- Neurosurgery
Background:
- High-grade meningiomas are challenging to manage, often recurring after standard treatments.
- Boron neutron capture therapy (BNCT) offers a tumor-selective particle radiation approach.
Purpose of the Study:
- To evaluate the efficacy of BNCT in treating recurrent high-grade meningioma.
- To assess tumor response, survival rates, and failure patterns following BNCT.
Main Methods:
- BNCT was administered 28 times to 20 patients with recurrent high-grade meningioma.
- (18)F-BPA PET scans were used to assess tumor uptake of the therapeutic compound.
- Tumor volume reduction, survival, and clinical outcomes were evaluated post-treatment.
Main Results:
- 18 of 19 cases showed good BPA uptake, indicating suitability for BNCT.
- A mean tumor volume reduction of 64.5% was observed within 2 months.
- Median survival after BNCT was 14.1 months; symptomatic improvement was noted in treated patients.
Conclusions:
- BNCT demonstrates potential as an effective treatment for high-grade meningioma.
- The therapy achieved significant tumor shrinkage and symptom relief in recurrent cases.
- Further investigation into BNCT's role in managing high-grade meningiomas is warranted.
